Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT?

摘要

A Diabetes Outcome Progression Trial (ADOPT) was an international, multicenter, randomized, double-blind, head-to-head study of patients with newly diagnosed type 2 diabetes mellitus. Eligible patients were aged 30-75 years, with a fasting plasma glucose (FPG) level 7-10 mmol/l, and no previous pharmacotherapy for type 2 diabetes mellitus. Patients with congestive heart failure, uncontrolled hypertension, angina, renal impairment, or liver disease were excluded. Patients were randomly allocated to receive one of three monotherapies: 4 mg rosiglitazone daily, 500 mg metformin daily, or 2.5 mg glyburide daily. Doses were adjusted to maintain an FPG level <7.8 mmol/l.